WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

  
                                    
                                          
<ARTICLE>                     5           
<LEGEND>                                  
 
                             Financial Data Schedule
                    Mylan Laboratories Inc. and Subsidiaries
                          Article 5 of Regulation S-X

     The schedule  contains  summary  financial  information  extracted from the
Consolidated  Balance Sheets at June 30, 1997 and the Consolidated  Statement of
Earnings  for the three  months  ended  June 30,  1997 and is  qualified  in its
entirety by reference to such financial statements.
                                          
</LEGEND>                                 
<CIK>                         0000069499  
                                          
                                        
<PERIOD-TYPE>                       3-MOS            
<FISCAL-YEAR-END>                   MAR-31-1998             

<PERIOD-END>                        JUN-30-1997              
                                               
<CASH>                               108,995,000             
<SECURITIES>                          15,062,000             
<RECEIVABLES>                        117,461,000             
<ALLOWANCES>                          10,432,000             
<INVENTORY>                          121,274,000             
<CURRENT-ASSETS>                     380,301,000             
<PP&E>                               203,793,000             
<DEPRECIATION>                        64,686,000             
<TOTAL-ASSETS>                       787,492,000             
<CURRENT-LIABILITIES>                 81,929,000             
<BONDS>                               39,744,000             
<PREFERRED-MANDATORY>                          0             
<PREFERRED>                                    0              
<COMMON>                              61,412,000             
<OTHER-SE>                           611,215,000             
<TOTAL-LIABILITY-AND-EQUITY>         787,492,000             
<SALES>                              109,188,000             
<TOTAL-REVENUES>                     109,188,000             
<CGS>                                 61,379,000             
<TOTAL-COSTS>                         61,379,000         
<OTHER-EXPENSES>                      31,429,000         
<LOSS-PROVISION>                               0         
<INTEREST-EXPENSE>                       758,000         
<INCOME-PRETAX>                       22,341,000         
<INCOME-TAX>                           5,743,000         
<INCOME-CONTINUING>                   16,598,000         
<DISCONTINUED>                                 0         
<EXTRAORDINARY>                                0         
<CHANGES>                                      0         
<NET-INCOME>                          16,598,000         
<EPS-PRIMARY>                                .14         
<EPS-DILUTED>                                .14